By Gary D. Novack, PhD
    Subspecialty Day 2011: Glaucoma

    Dr. Gary Novack describes current implants under investigation for delivery of ocular hyoptensive drugs, including punctal plugs with a prostaglandin release, EyeGate and other ionophoretic technologies, bio-erodible systems, and the Replenish refillable implant. Due to the complexity and research cost of sustainable biocompatible devices, Dr. Novack believes availability of a drug delivery system for glaucoma is at least 4 years away. A neuroprotection treatment system is even further off.